Date Founded
2003

Innovation
NeoVista is developing a radiation therapy device for treating of the wet form of Age-related Macular Degeneration (ARMD), one of the leading causes of blindness in the world. NeoVista is currently conducting clinical trials under an Investigational Device Exemption approved by the FDA.

Funding
NeoVista has completed A, B, and C rounds of funding, raising a total of $53.1 million.

Contact
38875 Cherry Street
Newark, CA 94560
510.933.7600 phone

www.neovistainc.com